Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 6/20 | 0.66 |
| ▸ | FPR1 | P21462 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SLC34A1 | Q06495 | 2/20 | 0.42 |
| ▸ | SMO | Q99835 | 2/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4296277 | 0.80 | AR (1.00) | ARCYP1A2SLC34A1SMO | |
| SCHEMBL4239407 | 0.79 | AR (0.80) | ARCYP1A2SLC34A1SMOKDM4E | |
| SCHEMBL4233511 | 0.78 | AR (0.70) | ARCYP1A2SLC34A1SMOKDM4E | |
| SCHEMBL4234605 | 0.77 | AR (0.69) | ARCYP1A2SLC34A1SMOKDM4E | |
| SCHEMBL4236666 | 0.73 | AR (0.64) | ARSLC34A1 | |
| SCHEMBL4296326 | 0.71 | AR (0.58) | ARFPR1LMNACYP1A2SLC34A1 | |
| SCHEMBL4296324 | 0.71 | AR (0.58) | ARFPR1LMNACYP1A2SLC34A1 | |
| SCHEMBL4239222 | 0.71 | AR (0.58) | ARFPR1SMN1; SMN2SLC34A1KDM4E | |
| SCHEMBL4303853 | 0.71 | AR (0.60) | ARLMNASMN1; SMN2ALDH1A1SLC34A1 | |
| SCHEMBL4299115 | 0.71 | AR (0.60) | ARSLC34A1SMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270361-A1 | Substituted pyrazole derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20090270361-A1 | Substituted pyrazole derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270361-A1 | Substituted pyrazole derivatives and use thereof | CBR3, CBR1, NOX5 | AR 622/4885FPR1 463/4885LMNA 4258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.